Gene Expression Profiling of Peritoneal Metastases from Appendiceal and Colon Cancer Demonstrates Unique Biologic Signatures and Predicts Patient Outcomes

被引:72
作者
Levine, Edward A. [1 ]
Blazer, Dan G., III [2 ]
Kim, Mickey K. [3 ]
Shen, Perry [1 ]
Stewart, John H. [1 ]
Guy, Cynthia [4 ]
Hsu, David S. [3 ]
机构
[1] Wake Forest Univ, Surg Oncol Serv, Dept Gen Surg, Winston Salem, NC 27157 USA
[2] Duke Univ, Dept Surg, Durham, NC USA
[3] Duke Univ, Dept Med Oncol, Durham, NC USA
[4] Duke Univ, Dept Pathol, Durham, NC 27706 USA
关键词
HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; PSEUDOMYXOMA PERITONEI; CYTOREDUCTIVE SURGERY; SYSTEMIC CHEMOTHERAPY; SINGLE-INSTITUTION; PROGNOSTIC-FACTORS; COLORECTAL-CANCER; TREFOIL FACTOR-1; CARCINOMATOSIS; ORIGIN;
D O I
10.1016/j.jamcollsurg.2011.12.028
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Treatment of peritoneal metastases from appendiceal and colon cancer with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) shows great promise. Although long-term disease-free survival is achieved in some cases with this procedure, many patients have recurrence. Oncologists have treated such recurrences of appendiceal cancer similarly to colorectal carcinoma, which has been largely ineffective. This study uses gene expression analysis of peritoneal metastases to better understand these neoplasms. STUDY DESIGN: From a prospectively maintained database and tissue bank, 41 snap frozen samples of peritoneal metastases (26 appendiceal, 15 colorectal) from patients undergoing HIPEC with complete cytoreduction and more than 3 years of follow-up underwent global gene expression analysis. Distinct phenotypes were identified using unsupervised hierarchical clustering based on differential gene expression. Survival curves restratified by genotype were generated. RESULTS: Three distinct phenotypes were found, 2 consisting of predominantly low grade appendiceal samples (10 of 13 in Cluster 1 and 15 of 20 in Cluster 2) and 1 consisting of predominantly colorectal samples (7 of 8 in Cluster 3). Cluster 1 consisted of patients with good prognosis and Clusters 2 and 3 consisted of patients with poor prognosis (p = 0.006). Signatures predicted survival of low- (Cluster 1) vs high-risk (Cluster 2) appendiceal (p = 0.04) and low-risk appendiceal (Cluster 1) vs colon primary (Cluster 3) (p = 0.0002). CONCLUSIONS: This study represents the first use of gene expression profiling for appendiceal cancer, and demonstrates genomic signatures quite distinct from colorectal cancer, confirming their unique biology. Consequently, therapy for appendiceal lesions extrapolated from colonic cancer regimens may be unfounded. These phenotypes may predict outcomes guiding patient management. (J Am Coll Surg 2012; 214: 599-607. (C) 2012 by the American College of Surgeons)
引用
收藏
页码:599 / 606
页数:8
相关论文
共 31 条
  • [1] Pseudomyxoma peritonei: Clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Baratti, Dario
    Kusamura, Shigeki
    Nonaka, Daisuke
    Langer, Martin
    Andreola, Salvatore
    Favaro, Miriam
    Gavazzi, Cecilia
    Laterza, Barbara
    Deraco, Marcello
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (02) : 526 - 534
  • [2] Pseudomyxoma peritonei of appendiceal origin: A clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review
    Bradley, RF
    Stewart, JH
    Russell, GB
    Levine, EA
    Geisinger, KR
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (05) : 551 - 559
  • [3] CHU DZJ, 1989, CANCER-AM CANCER SOC, V63, P364, DOI 10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO
  • [4] 2-V
  • [5] Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study
    Elias, Dominique
    Gilly, Francois
    Boutitie, Florent
    Quenet, Francois
    Bereder, Jean-Marc
    Mansvelt, Baudouin
    Lorimier, Gerard
    Dube, Pierre
    Glehen, Olivier
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 63 - 68
  • [6] Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin
    Elias, Dominique
    Lefevre, Jeremie H.
    Chevalier, Julie
    Brouquet, Antoine
    Marchal, Frederic
    Classe, Jean-Marc
    Ferron, Gwenael
    Guilloit, Jean-Marc
    Meeus, Pierre
    Goere, Diane
    Bonastre, Julia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 681 - 685
  • [7] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion Versus Systemic Chemotherapy Alone for Colorectal Peritoneal Carcinomatosis
    Franko, Jan
    Ibrahim, Zuhaib
    Gusani, Niraj J.
    Holtzman, Matthew P.
    Bartlett, David L.
    Zeh, Herbert J., III
    [J]. CANCER, 2010, 116 (16) : 3756 - 3762
  • [8] Toward Curative Treatment of Peritoneal Carcinomatosis From Nonovarian Origin by Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy A Multi-Institutional Study of 1290 Patients
    Glehen, Olivier
    Gilly, Francois N.
    Boutitie, Florent
    Bereder, Jean M.
    Quenet, Francois
    Sideris, Lucas
    Mansvelt, Baudouin
    Lorimier, Gerard
    Msika, Simon
    Elias, Dominique
    [J]. CANCER, 2010, 116 (24) : 5608 - 5618
  • [9] PSEUDOMYXOMA PERITONEI - LONG-TERM PATIENT SURVIVAL WITH AN AGGRESSIVE REGIONAL APPROACH
    GOUGH, DB
    DONOHUE, JH
    SCHUTT, AJ
    GONCHOROFF, N
    GOELLNER, JR
    WILSON, TO
    NAESSENS, JM
    OBRIEN, PC
    VANHEERDEN, JA
    [J]. ANNALS OF SURGERY, 1994, 219 (02) : 112 - 119
  • [10] Validation Study of a Quantitative Multigene Reverse Transcriptase-Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
    Gray, Richard G.
    Quirke, Philip
    Handley, Kelly
    Lopatin, Margarita
    Magill, Laura
    Baehner, Frederick L.
    Beaumont, Claire
    Clark-Langone, Kim M.
    Yoshizawa, Carl N.
    Lee, Mark
    Watson, Drew
    Shak, Steven
    Kerr, David J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (35) : 4611 - 4619